Zhengye Biotechnology Holding Limited (ZYBT)
| Market Cap | 212.25M |
| Revenue (ttm) | 36.79M |
| Net Income (ttm) | 6.35M |
| Shares Out | 47.17M |
| EPS (ttm) | 0.13 |
| PE Ratio | 33.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ZYBT
Zhengye Biotechnology Holding, through its operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of livestock by offering a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas, to Vietnam, Pakistan, and Egypt. [Read more]
News
Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO
Zhengye Biotechnology Holding Limited has filed for a $20 million IPO to raise capital for its acquisition program and new development capabilities. The company's revenue has declined, but it still ma...
Chinese animal health company Zhengye Biotechnology Holding files for a $20 million US IPO
Zhengye Biotechnology Holding, a Chinese provider of veterinary vaccines with a focus on livestock, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering.
Zhengye Biotechnology IPO Registration Document (F-1)
Zhengye Biotechnology has filed to go public with an IPO on the NASDAQ.